We developed a new approach to bioluminescent T cell imaging using a membrane-anchored form of the Gaussia luciferase (GLuc) enzyme, termed extGLuc, which we could stably express in both mouse and human primary T cells. In vitro, extGLuc + cells emitted significantly higher bioluminescent signal when compared to cells expressing GLuc, Renilla luciferase (RLuc) or membrane-anchored RLuc (extRLuc). In vivo, mouse extGLuc + T cells showed higher bioluminescent signal when compared to GLuc + and RLuc + T cells. Application of this imaging approach to human T cells genetically modified to express tumor-specific chimeric antigen receptors (CARs) enabled us to show in vivo CAR-mediated T cell accumulation in tumor, T cell persistence over time and concomitant imaging of T cells and tumor cells modified to express firefly luciferase. This sensitive imaging technology has application to many in vivo cell-based studies in a wide array of mouse models.
Bioluminescent imaging of cells modified to express luciferase enzymes allows for noninvasive monitoring of cells after adoptive transfer into mice. Firefly luciferase (FFLuc), derived from the firefly Photinus pyralis, which catalyzes the substrate luciferin 1 , is the most extensively used luciferase enzyme in cell-based bioluminescent imaging. Although effective in monitoring immortalized cells in vivo [2] [3] [4] , the application of FFLuc to T cell imaging has been largely restricted to the study of T cell populations derived from transgenic FFLuc + mice, T cell hybridomas and highly selected clonal FFLuctransfected human T cells [5] [6] [7] [8] [9] [10] [11] . Furthermore, the signal in T cells is markedly lower when compared to other FFLuc + hematopoetic cells or tumor cells 6, 11 , and efforts by investigators to introduce the gene encoding FFLuc into primary T cells have been compromised by poor gene expression 12 .
RLuc, derived from the anthozoan sea pansy Renilla reniformis, catalyzes coelenterazine, a substrate distinct from luciferase 1 . Although RLuc is readily expressed by primary T cells, its use in T cell bioluminescent imaging is compromised by low signal intensity, impairing imaging of cells in deeper tissues and thereby restricting imaging of T cell trafficking to superficial tumors 13 . The humanized GLuc enzyme, derived from the copepod Gaussia princeps, likewise uses coelenterazine as a substrate but emits a markedly more intense signal and may therefore overcome the limitations associated with RLuc 14 . However, the native GLuc enzyme is secreted 14 , markedly attenuating the in vivo bioluminescent signal of cells that express the enzyme.
In this report, we show that this limitation may be overcome by genetically engineering GLuc through the addition of a CD8 transmembrane domain to the carboxy terminus of the enzyme, allowing for retention of the resulting luciferase construct, extGLuc, at the cell surface. We show that extGLuc + T cells are rapidly generated from both mouse and human primary T cells and have a markedly superior in vivo bioluminescent signal when compared to GLuc + and RLuc + T cells. We further use this technology to show dual imaging of extGLuc + T cell and targeted FFLuc + tumor cell populations within the same mouse.
RESULTS

In vitro comparison of extGLuc to GLuc and RLuc
We transduced SFG retroviral constructs 15 containing the genes encoding GLuc, extGLuc, RLuc, extRLuc and GFP-FFLuc (Fig. 1a) into retrovirus-producing fibroblast cells (PG-13 cells). Cultured GLuc + and extGLuc + fibroblasts emitted a significantly enhanced bioluminescent signal when compared to RLuc + and extRLuc + fibroblasts (Fig. 1b,c) . After subtraction of background signal present in the medium, extGLuc + fibroblasts emitted a 100-fold greater signal when compared to fibroblasts expressing either RLuc or extRLuc and a more than ninefold increased signal when compared to GLuc + fibroblasts (Fig. 1c) .
Fibroblasts expressing extGLuc and GLuc showed a plateau signal of 10 min, representing a more than tenfold increased signal when compared to fibroblasts expressing RLuc (Fig. 1d) . Surface expression of the extGLuc construct was verified by comparing the ability of a GLuc-specific monoclonal antibody to bind to human T cells retrovirally transduced to express either extGLuc or GLuc enzymes with GFP or extGLuc alone as assessed by FACS (Fig. 1e) and immunohistochemical (Fig. 1f) analyses. Both the FACS and the immunohistochemical studies show binding of the antibody to the cell surface of extGluc + but not GLuc + T cells.
Enhanced signaling by extGLuc + T cells in vivo
We compared in vivo bioluminescent signal from C57/BL6 primary T cells transduced to express extGLuc, RLuc or GLuc after intravenous injection into major histocompatibility complex-mismatched severe combined immunodeficient (SCID)-beige mice, which have the SCID mutation resulting in a lack of functional T and B lymphocytes and the beige mutation resulting in impaired natural killer cell function, generating in vivo T cell expansion as a result of graft-versus-host disease. All T cell groups had similar gene transfer, and infused T cells were normalized to the GFP + fraction (data not shown). Comparison to T cells transduced with the SFG GFP-FFLuc construct was not performed, owing to poor gene transfer efficiencies (o3%; data not shown). We found a statistically significant greater bioluminescent signal (6-17-fold) in mice infused with extGLuc + T cells compared to mice infused with either RLuc + or GLuc + T cells (Fig. 2a,b) .
Whereas we noted a signal decay in the extGLuc + T cell-infused mice over time (Fig. 2c) , 450% of the signal was retained at 4 min after bolus intravenous injection of coelenterazine (Fig. 2d) . Once more, the extGLuc + T cell signal was 415-fold greater over 2-3 min after substrate infusion than that seen in mice infused with either RLuc + or GLuc + alloreactive C57/BL6 T cells (Fig. 2d) . We further showed the presence of extGLuc + T cells in tissues typically involved with graft-versus-host disease by bioluminescent imaging (Fig. 2e ) and histological analyses (Fig. 2f) at autopsy.
In vivo trafficking of extGLuc + DO11.10 T cells We subcutaneously injected SCID-beige mice with A20 mouse lymphoma tumor cells expressing ovalbumin (OVA; A20(OVA) cells) in the right flank and, as a control, A20 tumor cells expressing GFP (A20(GFP) cells) in the left flank. At day 7, we intravenously injected mice with extGLuc + OVA-specific DO11.10 T cells. Bioluminescent imaging showed initial T cell localization to the lungs that decreased over time with a progressively increasing signal in the A20(OVA) tumor, consistent with either migration of T cells to the OVA + tumor or proliferation of T cells within the tumor (Fig. 3a) . We assessed tumor size by positron emission tomography (PET) before and at day 7 after T cell infusion and observed a stable 2-[ 18 F]-fluoro-2-deoxy-D-glucose ( 18 FDG) signal in the targeted A20(OVA) tumor (Fig. 3b) , consistent with the antitumor activity of DO11.10 T cells and in contrast to the progressive signal observed in the A20(GFP) tumor (Fig. 3c) . We confirmed the presence of DO11.10 T cells in the A20(OVA) tumor but not in the A20(GFP) control tumor by immunohistochemistry at autopsy (Fig. 3d) .
To show the utility of T cell imaging with extGLuc in the context of a competent immune system, we injected BALB/c mice with wild-type A20 tumor (in the left flank) or A20(OVA) tumor (in the right flank), followed by intravenous infusion of extGLuc + DO11.10 T cells 7 d later. Once again, bioluminescent images, obtained 2 and 3 d after T cell infusion, showed infiltration of extGLuc + DO11.10 T cells in the A20(OVA) but not the wild-type A20 tumor (Fig. 3e) .
In vivo monitoring of tumor-targeted extGLuc + human T cells Human T cells genetically modified to express a CD19-targeted chimeric antigen receptor (CAR), 19z1, can eradicate human systemic CD19 + Raji Burkitt's lymphoma tumors, which primarily localize to the bone marrow in SCID-beige mice 16 . SCID-beige mice bearing human systemic CD19 + acute lymphoblastic leukemia (NALM-6) tumors, which infiltrate the bone marrow, liver, spleen, lymph nodes, lungs and central nervous system, are more difficult to fully eradicate after infusion with T cells expressing either the first-generation 19z1 CAR 16 or the second-generation 1928z CAR, which has additional CD28-mediated co-stimulatory activity 17 .
To determine whether treatment failure in the NALM-6 tumor model is related to a defect in T cell accumulation at selected sites of 
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systemic tumor, we initially assessed whether human T cells, transduced to express both the 19z1 CAR and extGLuc, specifically accumulate in subcutaneous NALM-6 tumors in SCID-beige mice (Fig. 4a) . T cells transduced with the Pz1 CAR 18 specific to the prostate-specific membrane antigen and extGLuc served as a negative control. After T cell injection, only mice treated with 19z1 + extGLuc + T cells showed signal in the tumor (Fig. 4a) . We verified the presence of human T cells in the tumor of 19z1 + extGLuc + T cell-treated mice, but not Pz1 + extGLuc + T cell-treated mice, by immunohistochemistry (Fig. 4b) .
We next generated a bicistronic SFG construct containing the second-generation 1928z CAR, previously shown to have superior in vivo antitumor efficacy against the NALM-6 tumor cell line 17 , and extGLuc (1928zIRES-extGLuc; Fig. 5a ). T cells transduced with Pz1IRES-extGLuc served as a control. Expression of extGLuc on the T cell surface did not impair CAR-mediated T cell function, as determined by a standard 4 h 51 Cr release cytotoxicity assay (Fig. 5b) performed in triplicate wells with percentage cytotoxicity varying o10% within each dataset. Expansion studies after co-culture on artificial antigen-presenting cells (NIH-3T3 fibroblasts expressing CD19 and CD80 (refs. 16,17) ) and cytokine release profiles measuring interleukin-2 and interferon-g likewise showed similar results between activated 1928zIRES-extGLuc + and 1928z + T cells (data not shown).
We injected SCID-beige mice systemically with GFP-FFLuc + NALM-6 tumor 10 d before T cell infusion (day -10) and assessed tumor burden by bioluminescent imaging before T cell infusion (day 0). All genetically modified T cell populations before infusion retained a central memory phenotype (CD62L hi CCR7 + ) (data not shown). Bioluminescent imaging of 1928zIRES-extGLuc + T cell-treated mice, in contrast to control mice treated with Pz1IRES-extGLuc + T cells, showed signal coincident with FFLuc signal from the NALM-6 tumor on days 1 and 3 after T cell infusion consistent with specific accumulation, activation and possible proliferation of CD19-targeted T cells at systemic sites of tumor involvement, including the bone marrow, liver, spleen and lymph nodes (Fig. 5c) . Reduced 1928zIRES-extGLuc + T cell signal noted at these sites on images obtained at days 7 and 10 is probably due to tumor cell eradication at these sites, as evidenced by tumor cell bioluminescent imaging at day 11 (Fig. 5c) . Residual 1928zIRES-extGLuc + T cell signal in these latter images was observed in the abdomen (Fig. 5c) . Reimaging of NALM-6 tumor with luciferase at day 11 after T cell infusion showed isolated, persistent disease in the periodontal region in two of six mice (Fig. 5c ), a site that had no detectable bioluminescent T cell signal. The remaining mice had residual disease isolated solely in the bone marrow (n ¼ 1) or spleen (n ¼ 1), moderate disease at multiple anatomical sites (n ¼ 1) or no detectable disease (n ¼ 1) (data not shown). As expected, Pz1IRES-extGLuc + T cell-treated control mice at day 11 showed diffuse FFLuc bioluminescent signal consistent with tumor progression (Fig. 5c ). We killed several treated mice on day 4 after T cell infusion for immunohistochemical analysis. At this time point, in 1928zIRES-extGLuc + T cell-treated mice, but not in Pz1IRES-extGLuc + T celltreated mice, CD3 + T cells were abundantly present at all anatomical sites with extGLuc bioluminescent signal, including the bone marrow (Fig. 5d) , spleen and liver (data not shown). Consistent with the antitumor efficacy of the CD19-targeted T cells, scant FFLuc + tumor was evident in the bone marrow (Fig. 5d) , spleen and liver (data not shown) of 1928zIRES-extGLuc + T cell-treated mice, in contrast to abundant FFLuc + tumor present at these anatomical sites in control mice (Fig. 5d and data not shown) . At day 11 after tumor cell imaging, we killed the remaining mice and analyzed their tissues by immunohistochemistry. We detected the presence of modified T cells in the liver of 1928zIRES-extGLuc + T cell-treated mice, consistent with the extGLuc signal noted in the abdomen on days 7 and 10 ( Fig. 5c,d) . We identified abundant tumor but no T cells in the livers of Pz1IRES-extGLuc + T cell-treated mice (Fig. 5d) . These data directly show that tumor-targeted CARs specifically mediate accumulation of T cells to systemic tumor in vivo.
To rule out nonspecific human T cell trafficking to mouse secondary lymphoid tissues and to further confirm that the specificity of targeted T cell accumulation to sites of tumor involvement in lymphoid tissues was indeed mediated by the CAR, we assessed the pattern of CAR -human T cell trafficking in tumor-free SCID-beige mice. We infused tumor-free mice with extGLuc + T cells and observed a brief, isolated bioluminescent T cell signal only in the lungs at 15 min and 60 min after T cell infusion ( Supplementary Fig. 1a online), a finding confirmed by FACS analysis ( Supplementary  Fig. 1b) . No signal was noted elsewhere over the 48 h after extGluc + T cell infusion, including in mouse secondary lymphoid tissues ( Supplementary Fig. 2 online) .
DISCUSSION
Outside of the setting of transgenic FFLuc + mice, wherein the study of FFLuc + T cells is restricted to specific mouse strains 5, 6 , reports of bioluminescent imaging with FFLuc + T cells are largely limited to studies requiring previous FACS sorting of GFP-FFLuc + mouse primary T cells 19 or cloned FFLuc + transduced human T cells 11 . Notably, both approaches require protracted in vitro culture periods that may adversely affect T cell phenotype, thereby limiting the relevance of subsequent in vivo studies [20] [21] [22] .
To image primary T cells at high sensitivity, as well as to allow for dual T cell-FFLuc + tumor cell imaging, we studied the feasibility of using GLuc for T cell bioluminescent imaging. T cells expressing GLuc enzyme are rapidly generated by efficient retroviral transduction and expansion of both mouse and human primary T cells. GLuc emits a markedly enhanced signal intensity when compared to RLuc and has been employed in cellular secretion assays, protein-protein interaction assays and in in vivo antibody-directed bioluminescent imaging of tumor [23] [24] [25] [26] [27] . However, GLuc is secreted by the cell, and previously published studies have demonstrated that genetic modification of GLuc to restrict secretion, either through the deletion of the signal peptide or through the addition of a KDEL retention sequence, failed to enhance the cellular bioluminescent signal 14 .
Because GLuc generates a bioluminescent signal in an ATPindependent manner, we could harness this signal by anchoring the GLuc enzyme to the cell surface, an approach that may further overcome dampening of coelenterazine-based bioluminescent signals associated with the multidrug resistance MDR1 P-glycoproteinmediated efflux of the substrate 28 . We found that T cells transduced with the resulting extGLuc enzyme could be rapidly generated ex vivo, maintaining a favorable central memory phenotype, and allowed for sensitive in vivo detection even in deep tissues, although the blue-green emission characteristics of the extGLuc construct may ultimately limit the sensitivity of detection in deeper tissues at lower T cell concentrations.
Because the FFLuc luciferin and GLuc coelenterazine substrates do not cross react, we can also concomitantly image FFLuc + tumor and extGLuc + T cells within the same mouse. Of note, we were able to use this dual cell imaging technology to demonstrate CAR-mediated specific T cell accumulation to most sites of systemic tumor involvement, and that the unique, but probably clinically irrelevant, persistence of tumor in the periodontal area, seen in our tumor model as well as in others 17, 29 , was a result of failed T cell entry or accumulation to this site, a hypothesis we postulated in a previous publication 17 .
Finally, in contrast to alternative approaches of in vivo T cell imaging, including PET 30 and magnetic resonance imaging [31] [32] [33] , bioluminescent imaging as an imaging modality is readily accessible, financially feasible, allows for retained sensitivity over time with minimal background signal and is amenable to concomitant imaging of two distinct cell populations. We conclude that the new technology presented here represents a potent and readily used advance in the imaging of primary T cells.
METHODS
Generation of luciferase retroviral constructs. We subcloned the genes encoding GFP-FFLuc (Clontech Laboratories), humanized GLuc (Nanolight Technology) and RLuc (Promega Corporation) into the SFG retroviral vector 15 . To generate the extGLuc construct, we replaced the GLuc native signal peptide with residues 1-18 of the human CD8 leader peptide and removed the 3¢ GLuc stop codon by PCR. We fused the CD8 transmembrane domain corresponding to amino acids 137-212 with an additional stop codon at the 3¢ end to the resulting PCR product by overlapping PCR. We generated the extRLuc construct in a similar manner. Using restriction enzyme digestion and ligation, we inserted an internal ribsomal entry site (IRES; Clontech Laboratories) humanized GFP (hrGFP; Stratagene) cassette distal to the GLuc, extGLuc, RLuc and extRluc constructs. We inserted an IRES-extGLuc cassette, generated by overlapping PCR, distal to the CAR-encoding gene to construct 1928zIRES-extGLuc and Pz1IRES-extGLuc.
Retroviral gene transduction. We transfected Phoenix-Eco cells with SFG plasmid DNA with ProFection Mammalian Transfection Systems (Promega Corporation). We generated modified T cells from mouse splenocytes after red blood cell lysis with ACK lysing buffer (Bio Whittaker), passage through nylon wool columns (Polysciences), activation with mouse CD3/CD28 T cell Expander magnetic beads (Invitrogen Dynal) and transduction with Phoenix-Eco retroviral supernatants 16, 34 . We generated PG-13 retroviral producer cell lines as previously described 35 .
We performed retroviral transduction of healthy human donor T cells obtained with informed consent under the MSKCC Institutional Review Board-approved protocol 90-095, using PG-13 retroviral supernatants 34 . We subsequently expanded transduced T cells by co-culture on artificial antigenpresenting cells 16 .
Flow cytometry. We performed FACS with a FACScan cytometer with Cellquest software (BD Biosciences), using a GLuc-specific mouse monoclonal antibody (Nanolight Technology) followed by phycoerythrin-conjugated goat sera specific to mouse IgG (Caltag Laboratories) or phycoerythrin-labeled CAR-specific monoclonal antibody 12D11 (MSKCC monoclonal antibody core facility). We blocked cell suspensions obtained from mouse tissues with BD CD16/CD32 Mouse Fc Block (BD Pharmingen) before staining with human CD3 specific antibody (Caltag).
In vivo mouse models. For in vivo studies, we used 8-12-week-old Fox Chase CB-17 (SCID-beige), C57/BL6, DO11.10 and BALB/c mice (Taconic). In graft-versus-host disease studies, we injected 5 Â 10 6 extGLuc + GFP + C57/BL6-derived T cells by tail vein into SCID-beige or BALB/c mice. We generated all A20 tumors by subcutaneous injection of 1 Â 10 6 A20 tumor cells and treated them with 5 Â 10 6 GFP + extGLuc + DO11.10 OVA-specific transgenic T cells. We injected SCID-beige mice with 5 Â 10 7 NALM-6 tumor cells to generate subcutaneous tumors followed by intravenous infusion of 1 Â 10 7 CAR-extGLuc + T cells at day 14. For systemic GFP-FFLuc + NALM-6 tumor studies, we intravenously injected SCID-beige mice with 1 Â 10 6 tumor cells followed 10 d later by 1 Â 10 7 transduced T cells. All mouse studies were performed in the context of an MSKCC Institutional Animal Care and Use Committee-approved protocol (00-05-065).
Bioluminescence imaging. We detected bioluminescence with a Xenogen IVIS Imaging System (Xenogen), as previously described 36 . We performed imaging either 10-15 s after bolus intravenous injection with coelenterazine (250 mg; Nanolight Technology) or 10-15 min after intraperitoneal injection of D-luciferin (150 mg kg -1 ; Xenogen). We imaged mice individually when we used coelenterazine substrate, whereas we imaged two to five mice simultaneously for luciferin-based acquisitions. The time of image acquisition was in the range of 0.5 min to 3 min. We used a field of view of 15, 20 or 25 cm with low, medium or high binning in an open filter to maximize signal intensity and sensitivity. We generated time-course studies of bioluminescent signal by obtaining one 30-s acquisition per min over 30-60 min. We performed in vitro bioluminescence imaging with similar acquisition parameters. We obtained acquisition of image data sets and measurement of signal intensity through region of interest analysis with Living Image software (Xenogen), and we normalized the images displayed on each data set according to color intensity.
Micro-positron emission tomography imaging. We imaged mice with a R4 microPET scanner (Concorde Microsystems) with 2-[ 18 F]-fluoro-2-deoxy-Dglucose ( 18 FDG) as described elsewhere 16 .
Cytotoxicity assays. We assessed the cytotoxicity of 1928zIRES-extGLuc-, 1928z-, Pz1IRES-extGLuc-and Pz1-transduced T cells by standard 4-h 51 Cr release assays as described elsewhere 16, 18 .
Cytokine detection. We conducted T cell cytokine secretion assays with the Luminex IS100 system with IS 2.3 software (Luminex) 17 .
Histology. H&E staining has been described elsewhere 17 . We probed fresh tissue samples embedded in optimal cutting temperature compound (Sigma-Aldrich) with biotinylated mouse antibody specific to human CD8 or mouse antibody specific to the DO11.10 T cell receptor (Caltag Laboratories). We probed cytospin preparations with mouse antibody specific to GLuc followed by horse sera specific to mouse IgG. We detected antibody with the ARK Peroxidase Kit (DakoCytomation). After unmasking of epitopes with citrate buffer (DakoCytomation; 10 mM, microwaved at high power for 15 min), we detected T cells and tumor cells in paraffinembedded mouse tissues with rabbit polyclonal sera specific to human CD3 (DakoCytomation) and rabbit polyclonal sera specific to FFLuc (MBL International) followed by secondary antibody application (biotinylated goat sera specific to rabbit IgG) with the Vectastain ABC Elite Kit System (Vector Laboratories).
Statistical analyses. We determined statistical significance of data by analysis of variance with SPSS software (SPSS).
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